NCT01477203View on ClinicalTrials.gov

Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders

PHASE4CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Major Depressive Disorder (MDD)Anxiety Disorder
Interventions
DRUG

Escitalopram

2-4 weeks, 5-10mg, max 20mg

Trial Locations (1)

1090

Medical University of Vienna, Department for Psychiatrie and Psychotherapie, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01477203 - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders | Biotech Hunter | Biotech Hunter